BRAINSTORM CELL THERAPEUTICS INC. Debt Instrument, Convertible, Beneficial Conversion Feature
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Debt Instrument, Convertible, Beneficial Conversion Feature of $407.00 thousand for the 12-month period ending 2007-12-31, per its 10-Q filed 2014-05-13.
Discontinued › Notes
us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature · last filed 2014-05-13
| Period end | Debt Instrument, Convertible, Beneficial Conversion Feature 9 month | Debt Instrument, Convertible, Beneficial Conversion Feature 12 month |
|---|---|---|
| 2007-12-31 | $407.00K 10-Q · filed 2014-05-13 | |
| 2006-12-31 | $1.09M 10-Q · filed 2014-05-13 | |
| 2006-03-31 | $164.00K 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |